Assertio Holdings, Inc. (NASDAQ: ASRT)

Assertio Holdings is a pharmaceutical company that provides commercial capabilities for differentiated products aimed at meeting patient needs. The company concentrates its marketing efforts on oncology supportive care therapies. It has assembled its product portfolio by acquiring or licensing approved drugs rather than developing new molecules from scratch. Its lead product ROLVEDON was obtained through the merger with Spectrum in July 2023. ROLVEDON is a long acting myeloid growth factor that links a granulocyte colony stimulating factor analog to the Fc fragment of human immunoglobulin G4. It is approved to lower the risk of infection manifested as febrile neutropenia in adult patients receiving anticancer drugs. Additional products include Sympazan an oral film formulation of clobazam for Lennox Gastaut Syndrome SPRIX a nasal spray of ketorolac for short term pain INDOCIN an indomethacin formulation for inflammatory conditions and CAMBIA a powder solution of diclofenac potassium for migraine treatment. The company also previously marketed Otrexup but stopped its commercialization in July 2025. In May 2025 Assertio Therapeutics was divested leaving Assertio Holdings focused on its remaining commercial operations.

Assertio Holdings generates revenue principally from the sale of its marketed pharmaceutical products. In the fiscal year 2025 the company reported net product sales of one hundred seventeen point one million dollars. ROLVEDON contributed sixty eight point two million dollars of that total. INDOCIN generated eighteen point nine million dollars and Sympazan contributed eleven point three million dollars. The remaining product lines SPRIX CAMBIA and the discontinued Otrexup made up the balance of sales. The company sells its products to three large national wholesale distributors that together account for the majority of its revenue. Cencora represented forty five percent of product sales in 2025 McKesson Corporation accounted for thirty one percent and Cardinal Health contributed ten percent. The remaining fourteen percent of sales came from other smaller distributors. These wholesalers in turn supply hospitals outpatient clinics pharmacies and other health care providers. Assertio Holdings maintains a dedicated sales force that engages with prescribers and health care professionals to stimulate demand for its products. The company does not operate its own manufacturing facilities and relies on third party contractors to produce its drugs.

Assertio Holdings occupies a niche within the broader pharmaceutical industry by focusing on specialty products that address specific therapeutic areas such as oncology supportive care neurology and pain management. Its lead product ROLVEDON competes against two other novel long acting granulocyte colony stimulating factor agents and six biosimilar versions of the same protein that are currently marketed in the United States. Additionally an approved but not yet marketed molecular entity could become a future competitor for ROLVEDON. In the NSAID market INDOCIN faces competition from generic indomethacin formulations as well as from opioid based therapies non narcotic analgesics and various anti inflammatory agents used for arthritis and gout. Sympazan contends with both branded and generic clobazam products as well as with alternative anti seizure medications surgical interventions neuromodulation and dietary therapies used for Lennox Gastaut Syndrome. SPRIX must contend with opioid based pain relievers transdermal opioid patches local anesthetic agents and other non narcotic analgesic options that treat short term moderate to severe pain. CAMBIA competes with a range of triptan medications that are available generically and with emerging calcitonin gene related peptide inhibitor therapies for migraine treatment. Despite this competitive landscape Assertio Holdings differentiates itself through a portfolio of differentiated approved products that require less internal research and development risk. The company leverages its commercial expertise to launch and promote these products effectively. It holds substantial patent protection for ROLVEDON with United States patents expected to expire in 2039 and a biologic exclusivity that extends to 2034. Similar patent lives protect Sympazan until 2040 CAMBIA until 2026 and SPRIX related manufacturing processes until 2029. These intellectual property rights combined with a focused sales force and established relationships with major wholesale distributors give Assertio Holdings a defensible position in its chosen markets.

The customer base of Assertio Holdings consists primarily of three large national wholesale distributors that purchase its products for resale to health care providers. Cencora McKesson Corporation and Cardinal Health are the principal wholesale partners and together they supplied approximately eighty six percent of the company’s product sales in 2025. The remaining distributors account for the rest of the volume. These wholesalers distribute the products to hospitals outpatient clinics pharmacies and other licensed health care settings where the drugs are ultimately administered to patients. Assertio Holdings also maintains direct relationships with prescribers and health care professionals through its sales force to help shape prescribing behavior and generate demand. While the company does not typically sell directly to end users it relies on the wholesale channel to reach its target audience of oncology clinics hematology practices neurology centers pain management facilities and migraine treatment centers.